logo

Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer

  4 days ago   
post image
DALLAS and SHANGHAI, Sept. 16, 2024 ( GLOBE NEWSWIRE ) -- Instil Bio, Inc. ( Nasdaq: TIL, "Instil" ) and ImmuneOnco Biopharmaceuticals ( Shanghai ) Inc. ( HKEX:1541, "ImmuneOnco" ) announced today the global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in ...
Ticker Sentiment Impact
TIL
Neutral
16 %